Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State
Recruiting
Phase 1
Interventional Study
Type 1 Diabetes Mellitis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 64
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 12 (estimated)
- Sponsor
- Gan and Lee Pharmaceuticals, USA · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This trial intends to investigate the pharmacodynamics, pharmacokinetics, safety, and tolerability of insulin GZR33 (hereafter referred to as GZR33) and estimate its potency in comparison with insulin degludec.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria: type 1 diabetes for at least 12 months
* 18-64 years of age
* HbA1c \<= 9.0%.
* Body Mass Index (BMI) between 18.5 and 29.0 kg/m\^2
* treated with a stable insulin regimen for at least 2 months, in a dose \> 0.2 and \< 1.2 U/kg/day
Exclusion Criteria:
* blood pressure outside …
Contacts